PDAC

2
Pipeline Programs
2
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

REVOLUTION Medicines
REVOLUTION MedicinesREDWOOD CITY, CA
1 program
1
TNG462Phase 1/2
Tango Therapeutics
Tango TherapeuticsMA - Cambridge
1 program
1
TNG462Phase 1/21 trial
Active Trials
NCT06922591Recruiting183Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
Tango TherapeuticsTNG462

Clinical Trials (1)

Total enrollment: 183 patients across 1 trials

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Start: May 2025Est. completion: Dec 2027183 patients
Phase 1/2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 183 patients
2 companies competing in this space